Radium-223 after first-line treatment for hormone-sensitive prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a drug called radium-223 for prostate cancer that has spread to the bonescars. It's for people who have already had a standard combination treatment and need another option. The goal is to see if adding radium-223 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have prostate cancer that has spread (metastatic) and is still hormone-sensitive.
- You have already had a combination of hormone therapy (ADT), chemotherapy (docetaxel), and a drug called darolutamide as your first treatment.
- You have completed at least 4 cycles of docetaxel within the last 12 weeks.
- You have at least 4 bone metastases on a bone scan.
- You are willing to take bone-protecting medication (like bisphosphonates or denosumab) along with calcium and vitamin D.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
This study looks at whether differences in a cancer’s DNA repair system can predict how well radium-223 works for men with prostate cancer that has spread to the bones. It may help researchers choose better treatment for people with bone metastatic, castration-resistant prostate cancer.
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This study uses a special type of scan (quantitative SPECT) to measure how Radium-223 (Xofigo) works in your bones. It helps doctors better understand treatment for prostate cancer that has spread to the bones.
This trial tests whether adding radiation therapy to the drug darolutamide helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and has spread to a few spots seen on special scans. The study aims to find the best way to control the cancer while keeping side effects manageable.
Hear when a new Metastatic Hormone-Sensitive Prostate Cance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.